Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2015 | Nov. 23, 2015 | |
Document And Entity Information [Abstract] | ||
Entity Registrant Name | CannaMED Enterprises, Inc. | |
Entity Central Index Key | 1,623,016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2015 | |
Document Fiscal Year Focus | 2,015 | |
Document Fiscal Period Focus | Q3 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 3,500,000 |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2015 | Dec. 31, 2014 |
CURRENT ASSETS | ||
Cash | ||
TOTAL ASSETS | ||
CURRENT LIABILITIES: | ||
Accounts payable and accrued expenses | ||
TOTAL LIABILITIES | ||
STOCKHOLDERS' EQUITY: | ||
Preferred stock, $0.0001 par value, 20,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014, respectively | ||
Common stock, $0.0001 par value, 100,000,000 shares authorized, 3,500,000 and 20,000,000 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively | $ 350 | $ 2,000 |
Discount on common stock | (350) | (2,000) |
Additional paid in capital | 2,812 | 712 |
Accumulated deficit | $ (2,812) | $ (712) |
Total Stockholders' Equity | ||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2015 | Dec. 31, 2014 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding | ||
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 3,500,000 | 20,000,000 |
Common stock, shares outstanding | 3,500,000 | 20,000,000 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2015 |
Income Statement [Abstract] | |||
REVENUES | |||
COST OF REVENUES | |||
GROSS PROFIT | |||
Operating expenses | $ 712 | $ 2,100 | $ 2,100 |
TOTAL OPERATING EXPENSES | 712 | 2,100 | 2,100 |
LOSS FROM OPERATIONS | $ (712) | $ (2,100) | $ (2,100) |
Interest and other expense (income) | |||
LOSS BEFORE PROVISION FOR INCOME TAXES | $ (712) | $ (2,100) | $ (2,100) |
Provision for income taxes | |||
NET LOSS | $ (712) | $ (2,100) | $ (2,100) |
NET LOSS PER SHARE OF COMMON STOCK - Basic and diluted | |||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and diluted | 20,000,000 | 13,364,130 | 17,755,515 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | Sep. 30, 2014 | Sep. 30, 2015 |
OPERATING ACTIVITIES: | ||
Net loss | $ (712) | $ (2,100) |
Changes in Operating Assets and Liabilities | ||
Accrued liability | 400 | |
Net cash provided by operating activities | $ (312) | $ (2,100) |
INVESTING ACTIVITIES: | ||
Net cash used in investing activities | ||
FINANCING ACTIVITIES: | ||
Proceeds from issuance of common stock | $ 2,000 | |
Proceeds from stockholders contribution | 312 | $ 2,100 |
Net cash provided by financing activities | 2,312 | $ 2,100 |
Net increase (decrease) in cash | $ 2,312 | |
Cash at beginning of period | ||
Cash at end of period | $ 2,000 | |
Supplemental disclosure of cash flow information: | ||
Cash paid for interest | ||
Cash paid for income tax |
Basis of Presentation and Organ
Basis of Presentation and Organization | 9 Months Ended |
Sep. 30, 2015 | |
Basis of Presentation and Organization [Abstract] | |
BASIS OF PRESENTATION AND ORGANIZATION | NOTE 1 – BASIS OF PRESENTATION AND ORGANIZATION Nature of Operations and Background During the period covered by this report, the Company changed its name from Redwood Valley Acquisition Corporation to CannaMED Enterprises, Inc. and effected a change in control. On August 24, 2015, the following events occurred which resulted in a change of control of the Company: 1. The officers and directors of Redwood Valley (the “Company”), James Cassidy and James McKillop, entered into a Share Purchase Agreement (the “SPA”) pursuant to which they entered into an agreement to sell an aggregate of 19,500,000 shares of their shares of the Company’s common stock to Mikhail Artamonov, at an aggregate purchase price of $75,000. These shares represented 98% of the Company’s issued and outstanding common stock. Effective upon the closing date of the Share Purchase Agreement, James Cassidy and James McKillop executed the agreement and owned 7% of shares of the Company’s stock, respectively, and Mikhail Artamonov, was the majority stockholder of the Company. 2. The Company redeemed and cancelled an aggregate of 19,500,000 of the then 20,000,000 shares of outstanding stock at a redemption price of $.0001 per share and cancelled such shares. The then current officers and directors resigned. 3. Mikhail Artamonov was named President, Secretary and Chief Financial Officer of the Company. Mikhail Artamonov serves as the Chief Executive Officer, Secretary, Chief Financial Officer and Director of the Company. On August 25, 2015, the Company issued 3,000,000 shares of its common stock at par representing 86% of the total outstanding 3,500,000 shares of common stock to Mikhail Artamonov, the sole officer and director of the Company. The company effected a change of control and changed its name to CannaMED Enterprises, Inc. (“CannaMED” or “the Company”). With this change of direction, the Company intends to consult with or effect a business combination with a private company to develop as medical cannabis industry innovators, utilizing the Company's team of healthcare and business professionals to start and/or source, research, evaluate and purchase products and companies. The Company will strive to develop environmentally friendly and economically sustainable business within the swiftly developing medical cannabis industry. The Company envisions to initially enter into joint ventures or acquire partial ownership in: ● a laboratory for medical cannabis testing, a pharmacy to perform research; ● a pharmacy to perform research and development of the newest medical cannabis formulations; ● a clinical practice to establish the network dispensaries; ● a packaging company; ● a research facility; and ● real estate to establish the foundation for the growing network Basis of Presentation – The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited Condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The interim Condensed Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Use of Estimates – The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Income Taxes – CannaMED accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), which requires the recognition of deferred tax liabilities and assets at currently enacted tax rates for the expected future tax consequences of events that have been included in the financial statements or tax returns. A valuation allowance is recognized to reduce the net deferred tax asset to an amount that is more likely than not to be realized. ASC 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. ASC 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Cash and Cash Equivalents – Cash and cash equivalents includes all highly liquid instruments with an original maturity of three months or less as of September 30, 2015. The Company did not have cash equivalents as of September 30, 2015 and December 31, 2014. Concentration of Risk– Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not have cash balances in excess of the Federal Deposit Insurance Corporation limit as of September 30, 2015 and December 31, 2014. Fair Value of Financial Instruments – The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses approximates their fair values due to their short-term maturities at September 30, 2015. Revenue Recognition – The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. Net Loss Per Share – Basic net loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed by dividing the loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Due to the Company’s losses in the periods presented, the Company currently has no dilutive securities and as such, basic and diluted loss per share are the same for such periods. |
Going Concern
Going Concern | 9 Months Ended |
Sep. 30, 2015 | |
Going Concern [Abstract] | |
GOING CONCERN | NOTE 2 – GOING CONCERN CannaMED has not yet generated any revenue since inception to date and has sustained operating loss. As of September 30, 2015, the Company had working capital of $0 and accumulated deficit of $2,812. The Company’s continuation as a going concern is dependent on its ability to generate sufficient cash flows from a business combination or other operations to meet its obligations and/or obtaining additional financing from its shareholders or other sources, as may be required. The accompanying condensed financial statements (unaudited) have been prepared assuming that the Company will continue as a going concern; however, the above condition raises substantial doubt about the Company's ability to do so. The condensed financial statements (unaudited) do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. In order to maintain its current level of operations, the Company will require additional working capital from either cash flow from operations, loans from officers, or from the sale of its equity. However, the Company currently has no commitments from any third parties for the purchase of its equity. If the Company is unable to acquire additional working capital, it will be required to significantly reduce its current level of operations. |
Recent Accounting Pronuncements
Recent Accounting Pronuncements | 9 Months Ended |
Sep. 30, 2015 | |
Recent Accounting Pronouncements [Abstract] | |
RECENT ACCOUNTING PRONOUNCEMENTS | NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09) “Revenue from Contracts with Customers.” ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-09 on our consolidated financial statements. In August, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), which now requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued. If conditions or events raise substantial doubt about an entity’s ability to continue as a going concern, and substantial doubt is not alleviated after consideration of management’s plans, additional disclosures are required. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. These requirements were previously included within auditing standards and federal securities law, but are now included within U.S. GAAP. We have evaluated our disclosures regarding our ability to continue as a going concern and concluded that we are in compliance with the disclosure requirements. There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows. |
Stockhoders' Equity
Stockhoders' Equity | 9 Months Ended |
Sep. 30, 2015 | |
Stockholders' Equity [Abstract] | |
STOCKHOLDERS' EQUITY | NOTE 4 – STOCKHOLDERS’ EQUITY Preferred Stock - Common Stock - The current ownership structure is as follows: Common Shares Percent James Cassidy 250,000 7 % James McKillop 250,000 7 % Mikhail Artamonov 3,000,000 86 % 3,500,000 100 % |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2015 | |
Commitments and Contingencies [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 5 – COMMITMENTS AND CONTINGENCIES Lease commitment The Company had no lease commitments as of September 30, 2015 and December 31, 2014. |
Income Tax
Income Tax | 9 Months Ended |
Sep. 30, 2015 | |
Income Tax [Abstract] | |
INCOME TAX | NOTE 6 – INCOME TAX Under ASC 740, "Income Taxes," deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2015 there were no deferred taxes due to the uncertainty of the realization of net operating loss or carry forward prior to expiration. |
Basis of Presentation and Org12
Basis of Presentation and Organization (Policies) | 9 Months Ended |
Sep. 30, 2015 | |
Basis of Presentation and Organization [Abstract] | |
Nature of Operations and Background | Nature of Operations and Background During the period covered by this report, the Company changed its name from Redwood Valley Acquisition Corporation to CannaMED Enterprises, Inc. and effected a change in control. On August 24, 2015, the following events occurred which resulted in a change of control of the Company: 1. The officers and directors of Redwood Valley (the “Company”), James Cassidy and James McKillop, entered into a Share Purchase Agreement (the “SPA”) pursuant to which they entered into an agreement to sell an aggregate of 19,500,000 shares of their shares of the Company’s common stock to Mikhail Artamonov, at an aggregate purchase price of $75,000. These shares represented 98% of the Company’s issued and outstanding common stock. Effective upon the closing date of the Share Purchase Agreement, James Cassidy and James McKillop executed the agreement and owned 7% of shares of the Company’s stock, respectively, and Mikhail Artamonov, was the majority stockholder of the Company. 2. The Company redeemed and cancelled an aggregate of 19,500,000 of the then 20,000,000 shares of outstanding stock at a redemption price of $.0001 per share and cancelled such shares. The then current officers and directors resigned. 3. Mikhail Artamonov was named President, Secretary and Chief Financial Officer of the Company. Mikhail Artamonov serves as the Chief Executive Officer, Secretary, Chief Financial Officer and Director of the Company. On August 25, 2015, the Company issued 3,000,000 shares of its common stock at par representing 86% of the total outstanding 3,500,000 shares of common stock to Mikhail Artamonov, the sole officer and director of the Company. The company effected a change of control and changed its name to CannaMED Enterprises, Inc. (“CannaMED” or “the Company”). With this change of direction, the Company intends to consult with or effect a business combination with a private company to develop as medical cannabis industry innovators, utilizing the Company's team of healthcare and business professionals to start and/or source, research, evaluate and purchase products and companies. The Company will strive to develop environmentally friendly and economically sustainable business within the swiftly developing medical cannabis industry. The Company envisions to initially enter into joint ventures or acquire partial ownership in: ● a laboratory for medical cannabis testing, a pharmacy to perform research; ● a pharmacy to perform research and development of the newest medical cannabis formulations; ● a clinical practice to establish the network dispensaries; ● a packaging company; ● a research facility; and ● real estate to establish the foundation for the growing network |
Basis of Presentation | Basis of Presentation – The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited Condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The interim Condensed Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. |
Use of Estimates | Use of Estimates – The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. |
Income Taxes | Income Taxes – CannaMED accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”), which requires the recognition of deferred tax liabilities and assets at currently enacted tax rates for the expected future tax consequences of events that have been included in the financial statements or tax returns. A valuation allowance is recognized to reduce the net deferred tax asset to an amount that is more likely than not to be realized. ASC 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. ASC 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. |
Cash and Cash Equivalents | Cash and Cash Equivalents – Cash and cash equivalents includes all highly liquid instruments with an original maturity of three months or less as of September 30, 2015. The Company did not have cash equivalents as of September 30, 2015 and December 31, 2014. |
Concentration of Risk | Concentration of Risk– Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not have cash balances in excess of the Federal Deposit Insurance Corporation limit as of September 30, 2015 and December 31, 2014. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments – The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses approximates their fair values due to their short-term maturities at September 30, 2015. |
Revenue Recognition | Revenue Recognition – The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. |
Net Loss Per Share | Net Loss Per Share – Basic net loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed by dividing the loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Due to the Company’s losses in the periods presented, the Company currently has no dilutive securities and as such, basic and diluted loss per share are the same for such periods. |
Stockhoders' Equity (Tables)
Stockhoders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2015 | |
Stockholders' Equity [Abstract] | |
Schedule of current ownership | Common Shares Percent James Cassidy 250,000 7 % James McKillop 250,000 7 % Mikhail Artamonov 3,000,000 86 % 3,500,000 100 % |
Basis of Presentation and Org14
Basis of Presentation and Organization (Details) - USD ($) | 1 Months Ended | ||||
Aug. 31, 2015 | Aug. 24, 2015 | Sep. 30, 2015 | Aug. 25, 2015 | Dec. 31, 2014 | |
Basis of Presentation and Organization (Textual) | |||||
Aggregate shares of common stock | 3,000,000 | ||||
Aggregate purchase price | $ 300 | ||||
Percentage of shares of common stock | 100.00% | ||||
Aggregate amount redeemed and cancelled | 19,500,000 | ||||
Common stock shares outstanding | 3,500,000 | 20,000,000 | |||
Common stock shares issued | 3,500,000 | 20,000,000 | |||
Mikhail Artamonov [Member] | |||||
Basis of Presentation and Organization (Textual) | |||||
Aggregate shares of common stock | 19,500,000 | ||||
Aggregate purchase price | $ 75,000 | ||||
Percentage of shares of common stock | 7.00% | ||||
Percenatage of issued and outstanding common stock | 98.00% | ||||
Aggregate amount redeemed and cancelled | 19,500,000 | ||||
Redemption price | $ 0.0001 | ||||
Common stock shares outstanding | 20,000,000 | 3,500,000 | |||
Common stock shares issued | 3,000,000 |
Going Concern (Details)
Going Concern (Details) - USD ($) | Sep. 30, 2015 | Dec. 31, 2014 |
Going Concern (Textual) | ||
Working capital | $ 0 | |
Accumulated deficit | $ 2,812 | $ 712 |
Stockhoders' Equity (Details)
Stockhoders' Equity (Details) - shares | Sep. 30, 2015 | Dec. 31, 2014 |
Other Ownership Interests [Line Items] | ||
Ownership Percentage | 100.00% | |
Common stock shares issued | 3,500,000 | 20,000,000 |
James Cassidy [Member] | ||
Other Ownership Interests [Line Items] | ||
Ownership Percentage | 7.00% | |
Common stock shares issued | 250,000 | |
James Mckillop [Member] | ||
Other Ownership Interests [Line Items] | ||
Ownership Percentage | 7.00% | |
Common stock shares issued | 250,000 | |
Mikhail Artamonov [Member] | ||
Other Ownership Interests [Line Items] | ||
Ownership Percentage | 86.00% | |
Common stock shares issued | 3,000,000 |
Stockhoders' Equity (Details Te
Stockhoders' Equity (Details Textuals) - USD ($) | 1 Months Ended | ||
Aug. 31, 2015 | Sep. 30, 2015 | Dec. 31, 2014 | |
Stockholders Equity (Textual) | |||
Preferred stock, shares authorized | 20,000,000 | 20,000,000 | |
Preferred stock, par value | $ 0.0001 | $ 0.0001 | |
Common stock, par value | $ 0.0001 | $ 0.0001 | |
Common stock, shares authorized | 100,000,000 | 100,000,000 | |
Common stock, shares issued | 3,500,000 | 20,000,000 | |
Common stock, shares outstanding | 3,500,000 | 20,000,000 | |
Common stock redeemed value | $ 1,950 | ||
Common stock redeemed | 19,500,000 | ||
Common stock issued value | $ 300 | ||
Common stock issued | 3,000,000 |